Liver Sinusoidal Endothelial Cell Lectin, LSECtin, Negatively Regulates Hepatic T-Cell Immune Response

LI TANG,* JUNTAO YANG,* WANLI LIU,†-T XIAOMING TANG,* JIE CHEN,* DIANYUAN ZHAO,* MIN WANG,* FENG XU,* YANTAO LU,* BIAO LIU,* QIHONG SUN,* LINGQIANG ZHANG,* and FUCHU HE*§

*State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Beijing, China; ‡Sun Yat-sen University Cancer Center, Guangzhou, China; and the §Institutes of Biomedical Sciences, Fudan University, Shanghai, China

BACKGROUND & AIMS: The liver is an organ with paradoxical immunologic properties and is known for its tolerant microenvironment, which holds important implications for hepatic diseases. The molecular basis for this local immune suppression, however, is poorly understood. In this study, we aimed to determine the role of liver sinusoidal endothelial cell lectin (LSECtin), a recently identified member of the dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN) family, in the regulation of hepatic T-cell immune response.

METHODS: The regulation of T-cell effector function by LSECtin was determined by co-stimulated T cells with anti-CD3/CD28 monoclonal antibody and LSECtin protein, or co-culture of T-cell receptor transgenic T cells with mouse LSECs in vitro. We generated LSECtin knockout mice and prepared recombinant LSECtin protein and complementary DNA plasmids to analyze the role of LSECtin in hepatic T-cell immune regulation.

RESULTS: We showed that LSECtin specifically recognized activated T cells and negatively regulated their immune responses. In mice with T-cell–mediated acute liver injury, the lack of LSECtin accelerated the disease owing to an increased T-cell immune response, whereas the exogenous administration of recombinant LSECtin protein or plasmid ameliorated the disease via down-regulation of T-cell immunity.

CONCLUSIONS: Our results reveal that LSECtin is a novel regulator of T cells and expose a crucial mechanism for hepatic T-cell immune suppression, perhaps opening up a new approach for treatment of inflammatory diseases in the liver.

Accumulating evidence indicates that the liver is an important immune organ that favors the induction of tolerance rather than immunity,1–3 which is critical for maintaining immunologic silence in response to harmless antigenic material present in food. The immune tolerance of the liver also might account for the survival of liver allografts and diverse hepatic inflammatory diseases,4 which highlights the importance of understanding the nature of hepatic immune regulation. Two crucial mechanisms have been proposed for liver tolerance. First, the liver is unlike any other organ in the T-cell biology, as best illustrated by inactivation, tolerance, and apoptosis.4

Second, liver sinusoidal endothelial cells (LSECs) and Kupffer cells play significant roles in the distinctive constraints on hepatic T cells.5–8 The exact molecular mechanisms underlying the hepatic T-cell immune regulation, however, have not been elucidated.

T-cell immune regulation is regulated precisely through a variety of mechanisms, and cell-surface regulators such as co-signaling molecules have been identified as crucial components. Even so, the understanding of cell-surface regulators for T-cell immunity has been greatly expanded by the introduction of the lectin superfamily.9 For example, the C-type lectin macrophage galactose-type C-type lectin (MGL) on dendritic cells (DCs) negatively regulates effector T cells via interaction with CD45.10 A genomewide association study identified the predicted C-type lectin KIAA0350 as a type 1 diabetes gene, suggesting its regulatory role in the activation of cytotoxic T cells.11 It is clear that lectins are crucial players in immune tolerance and homeostasis, and are involved in diseases of the immune system. It is noteworthy that several lectins also are localized to the liver, although no lectins have been confirmed to be T-cell regulators in the liver thus far.

We identified LSECtin from the liver, which belongs to the C-type lectin subfamily including CD23, dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN), and liver/lymph node-specific ICAM-3 grabbing nonintegrin (L-SIGN).12 Accumulating evidence suggests that this family is vital in the regulation of immune effector cells: DC-SIGN is essential for DC-induced T-cell prolif-

Abbreviations used in this paper: CLR, C-type lectin receptors; CRD, carbohydrate recognition domain; DC, dendritic cell; DC-SIGN, dendritic cell-specific ICAM-3 grabbing nonintegrin; EGTA, ethylene glycolbis(b-aminoethyl ether)-N,N,N’,N’-tetraacetic acid; IFN, interferon; IL, interleukin; L-SIGN, liver/lymph node specific ICAM-3 grabbing nonintegrin; LSEC, liver sinusoidal endothelial cell; mAb, monoclonal antibody; MGL, macrophage galactose-type C-type lectin; NF-κB, nuclear factor-κB; OVA, ovalbumin; PBL, peripheral blood lymphocyte; PBMC, peripheral blood mononuclear cell; PCR, polymerase chain reaction; PGK, phosphoglycerate kinase; PMA, phorbol-12-myristate-13-acetate; Q-PCR, quantitative PCR; SARS, severe acute respiratory syndrome; siRNA, small interfering; TCR, T-cell receptor; TNF, tumor necrosis factor; wt, wildtype.
LSECtin is controlled by the C-type lectin LSECtin. Results reveal a crucial mechanism by which hepatic T-cell disease by down-regulating T-cell immunity. Thus, our recombinant LSECtin protein or plasmid ameliorated the response, whereas the exogenous administration of re-adapted the disease owing to an increased T-cell immune mediated acute liver injury, the lack of LSECtin accelerates in liver in the absence of LSECtin. In mice with T-cell–mediated acute liver injury, the lack of LSECtin accelerated the disease owing to an increased T-cell immune response, whereas the exogenous administration of re-combinant LSECtin protein or plasmid ameliorated the disease by down-regulating T-cell immunity. Thus, our results reveal a crucial mechanism by which hepatic T-cell immunity is controlled by the C-type lectin LSECtin.

Materials and Methods

Cell Lines and Cell Preparation

The cell lines HL-60, U937, Daudi, Molt-4, CEM, Jurkat, CHO, and MCF7 were from American Type Culture Collection. Human LSECs were from Scientcell Research Laboratories (Carlsbad, CA). CD4+ and CD8+ subsets or total T cells were purified using the MACS beads system (Miltenyi Biotech, Bergisch Gladbach, Germany). Mouse LSECs were prepared as reported previously.1

Monoclonal Antibodies, Reagents, Immunoglobulin Fusion Proteins, and Plasmids

The monoclonal antibody (mAb) against CD3 (h: HIT3a; m: 500A2), anti-CD4 (RPA-T4), anti-CD8 (RPA-T8), anti-CD69 (FN50), and anti-CD25 (MA251) were from BD Pharmingen (San Jose, CA). The mAb against CD28 (ANC28.1/SD10) was from Calbiochem (San Diego, CA). Anti-mouse interleukin (IL)-2 (JES6-5H4), tumor necrosis factor (TNF)-α (MP6-XT22), and interferon (IFN)-γ (AN18.17.24) were from MACS. Anti-mouse CD3 (145–2C11), anti-mouse CD4 (L3T4), anti-mouse CD8 (Ly-2), anti-mouse CD44 (IM7), anti-DO11.10 T-cell receptor (TCR) (KJ1-26), and the mAb against CD28 (37.51) were from eBioscience (San Diego, CA). Male Balb/C mice were injected with an optimum dose (18 mg/kg) of Con A (Sigma–Aldrich, St. Louis, MO) via the tail vein. A reduced dose (8 mg/kg) of Con A was used in KO mice. The small interfering RNAs (siRNAs) or the LSECtin cDNA plasmid were delivered in vivo as described.17,18
(ALT)/aspartate aminotransferase (AST) levels were estimated using a detection kit.

**Statistical Analyses**

A Student $t$ test and 1-way analysis of variance with the Tukey post hoc test were used for statistical analysis. Results with a $P$ value of less than .05 were considered as statistically significant.

**Results**

**LSECtin Binds to Activated T Cells Via a Protein–Glycan Interaction**

Characterization of LSECtin family members such as DC-SIGN suggest that LSECtin might act as a cell adhesion molecule in the immune system. To test this hypothesis we screened a series of cell lines to identify the LSECtin ligand by flow cytometry. We found that LSECtin–Fc interacted with the CEM and Jurkat T cell lines (Figure 1A). Moreover, when tested after stimulation with phorbol-12-myristate-13-acetate (PMA) combination with ionomycin, Jurkat T cells showed markedly increased binding of LSECtin, and this binding required the presence of Ca$^{2+}$ because it was inhibited by addition of the calcium chelator ethylene glycol-bis(b-aminoethyl ether)-$N,N',N''$-tetraacetic acid (EGTA) (Figure 1B). We then sought to determine whether LSECtin receptor is expressed naturally on T cells in vivo. By using flow cytometry analysis, we found that LSECtin–Fc specifically bound peripheral blood mononuclear cells (PBMCs) activated by PMA and ionomycin, and this interaction could be inhibited completely by the addition of EGTA (Figure 1C). However, LSECtin did not bind nonactivated PBMCs. To verify T-cell binding, we purified either CD4$^+$ or CD8$^+$ cells from PBMCs by positive selection using antibody-coated magnetic beads. LSECtin showed strong binding to activated CD4$^+$ and CD8$^+$ T cells (Figure 1D). To confirm the interaction of LSECtin and T cells at a cellular level, cell–cell adhesion experiments were performed to assess the adhesion of peripheral blood T cells to LSECtin transfectants. Activated peripheral blood T cells specifically adhered to MCF7 cells expressing LSECtin compared with background binding to parental MCF7 cells. This binding was inhibited by a blocking antibody to LSECtin (Figure 1E and F), confirming the specificity of the interaction.

LSECtin has a typical carbohydrate recognition domain (CRD) and binds mannose, GlcNAc, and fucose in a Ca$^{2+}$-dependent manner. Therefore, we sought to determine whether LSECtin binds to activated T cells through a pro-
tein–glycan interaction. The binding of LSECtin to activated T cells actually was prevented by EGTA and saccharides such as D-mannose, N-GlcNAc, and L-fucose (Figure 2A). To assess the contribution of N- or O-linked glycosylation in LSECtin adhesion, activated T cells were cultured in the presence of tunicamycin or benzyl-α-GalNAc, which could block the formation of proteins N- or O-glycosidic linkages, respectively. Tunicamycin abrogated the adhesion of T cells to LSECtin, whereas benzyl-α-GalNAc did not (Figure 2B). Amino acid sequence alignment of the CRD of LSECtin with that of other C-type lectins indicates that 4 amino acids, Glu254, Asn256, Asn274, and Asp275, interact with Ca\(^{2+}\) through their carbonyl groups, and Glu254/Asn256 exist in a conserved EPN motif, which is important for carbohydrate recognition. Thus, we generated a series of LSECtin point mutants, including N256D, N274D, and D275A, in the soluble isoform. Alteration of each residue completely abolished the binding of LSECtin–Fc to T cells (Figure 2C), compared with the control substitution L231A. These results indicate that LSECtin binds to activated T cells through a protein–glycan interaction.

**LSECtin Inhibits T-Cell Immune Response In Vitro**

Considering that LSECtin recognizes activated T cells, we investigated whether LSECtin regulates T-cell immune response. We cultured peripheral blood T cells with anti-CD3 mAb and LSECtin–Fc for 72 hours and found that the up-regulation of cell surface activation molecules, including CD69 and CD25, was inhibited by LSECtin (Figure 3A). Proliferation was estimated by incorporation of bromodeoxyuridine, and it was found that LSECtin significantly decreased T-cell proliferation stimulated by anti-CD3 (Figure 3B). To examine the effects of soluble LSECtin ligation on the production of cytokines, culture supernatants from T-cell proliferation assays, as shown previously, were harvested at 48 hours. Secretion of IFN-γ, IL-2, and IL-10 was inhibited significantly by LSECtin–Fc, although the production of transforming growth factor-β was not affected (Figure 3C). To further test whether LSECtin on the cell surface inhibits T-cell responses, we established a stably expressing CHO cell line of LSECtin (CHO–LSECtin). PBMCs were co-cultured with irradiated CHO–LSECtin cells or mock CHO cells and soluble anti-CD3 mAb for 48 hours. Membrane-bound LSECtin decreased the secretion of IFN-γ and IL-2 in the culture supernatants of PBMCs; on the other hand, its siRNA reversed this effect (Figure 3D). The negative effect of LSECtin also was observed in the presence of anti-CD28 mAb (Figure 3E), suggesting that the suppression cannot be overcome by co-stimulation. To study antigen-specific signals, we examined the effects of LSECtin on T cells that were expressing an OVA-specific TCR transgene. The secretion of IFN-γ and IL-2 was shown to be inhibited significantly by LSECtin–Fc (Figure 3F).

To illustrate the mechanism of LSECtin-mediated T-cell inhibition, we first examined tyrosine phosphorylation of proteins after stimulation via the TCR for 60 minutes. We examined TCR-mediated phosphorylation of ZAP-70, LCK, and PKCθ tyrosine kinase and found that the phosphorylation of these proteins was decreased (Figure 4A). ERK and JNK are 2 important downstream targets of TCR activation in response to TCR signals. The phosphorylation of ERK and JNK was up-regulated in activated T cells, whereas it was down-regulated by LSECtin engagement (Figure 4A). We also examined the TCR-mediated nuclear factor-κB (NF-κB) pathway. The phosphorylation of IκB was decreased, which is important for its proteasomal degradation and for the activation of NF-κB. Moreover, the expression of NF-κB target genes IL-2R, TNF-α, and IRF1 obviously was decreased using quantitative PCR (Q-PCR) assay (Figure 4A and B).

**Generation of LSECtin-Deficient Mice**

To determine the in vivo function of LSECtin, we generated LSECtin-deficient mice. Our gene targeting vec-
tor replaced the entire coding region (including all exons) of the endogenous LSECtin allele with a PGK-neo cassette, thereby deleting all functional domains of LSECtin (Figure 5A). Among 96 G418-resistant ES clones, 4 (4.1%) positive clones were obtained via Southern blot verification (Figure 5B). Chimeric male mice were derived from these ES clones by standard procedures. They were crossed to C57BL/6 females, and heterozygous mutant mice were established from targeted ES clone G8. Heterozygous and homozygous LSECtin mutant mice then were identified by PCR analysis of genomic DNA isolated from tail biopsies (Figure 5C). To confirm the absence of LSECtin in these mice, the expression of LSECtin in the liver was estimated by reverse-transcription PCR analysis. As expected, LSECtin was detected in wild-type (wt) but not in KO liver (Figure 5D). The loss of LSECtin protein in liver also was confirmed by immunofluorescence staining (Figure 5E). These mice initially were back-crossed to the C57BL/6 background for at least 6 generations before they were used in the studies described.

**LSECtin Limits the Hepatic T-Cell Immune Response In Vivo**

Our previous work showed that LSECtin messenger RNA is expressed in liver sinusoidal endothelial cells. Recent studies have indicated that LSECtin also is present in Kupffer cells, which was confirmed in our study (Supplementary Figures 1 and 2). LSECtin limited...
the activation of T cells in vitro, and the specific localization of LSECtin in the LSECs and Kupffer cells provided a very strong clue for its important function in the regulation of T-cell immune responses in the liver.

LSECtin KO mice displayed normal numbers and ratios of CD4⁺/CD8⁺, CD4⁺, and CD8⁺ T cells in the thymus. The T-cell populations in the spleen and lymph nodes also appeared to show normal numbers (Figure 6A). In contrast, an increase in CD4⁺ (42% in KO mice vs 37% in wt mice) and CD8⁺ (23% in KO mice vs 18% in wt mice) T cells were found in the liver, but no effect was detected in the lung and kidney. To determine the phenotype of accumulated T cells in the liver of LSECtin KO mice, we examined the expression of CD62L and CD44

Figure 4. LSECtin inhibits TCR-mediated signaling. (A) Tyrosine phosphorylation of proteins. T cells were incubated with anti-CD3 and anti-CD28 in the presence of LSECtin–Fc for 60 minutes before lysis in RIPA buffer. Cell lysates were analyzed by immunoblotting with phosphospecific, or pan antibodies against ZAP-70, LCK, PKCθ, Erk, JNK, and anti-pIκB. (B) Q-PCR analysis of changes in the expression of the NF-κB target genes IL-2R, TNF-α, and IRF1. The data shown are from 1 representative of 3 experiments.

Figure 5. Generation of LSECtin KO mice. (A) The targeting map of the LSECtin genomic locus. The whole coding region was replaced with PGK-neo cassette. RE sites: N, Nco I; Bg, Bgl II; RV, EcoR V. The short black bar indicates the external southern probe, and short arrows are genotyping primers. (B and C) Southern blot and PCR detection of heterozygous and homozygous LSECtin mutants in genomic DNA from targeted (B) embryonic stem (ES) cells and (C) mouse tails. (D and E) The expression of LSECtin in liver from wt or KO mice estimated by (D) reverse-transcription PCR analysis and (E) immunofluorescence staining.
on intrahepatic T cells. A fraction of intrahepatic T cells in LSECtin KO mice were CD62L<sub>lo</sub>CD44<sub>Hi</sub> in comparison with normal mice (60% vs 45%), although no difference was found in the spleen of the same mice (Figure 6A), suggesting that a large number of these T cells were activated. These results implicated that LSECtin could play a key role in the regulation of hepatic T-cell immunity.

Given that the amount of LSECtin present in the in vitro models could well have been nonphysiologic, we performed analyses using co-culture TCR transgenic T cells with KO or wt LSECs. The T cells co-cultured with KO LSECs showed higher responses than those cultured with wt LSECs, indicating that LSECtin on LSECs down-regulates T-cell immune responses (Figure 6B). The role of LSECtin in the regulation of T cells in liver was evaluated further in a DO11.10 TCR transgenic T-cell transfer system in which wt DO11.10 CD4<sup>+</sup> T cells were transferred into either wt or LSECtin KO mice. The mice subsequently were challenged with OVA peptide. We observed a significant increase in DO11.10 CD4<sup>+</sup> T cells in the liver of KO mice compared with wt mice on day 4 post-OVA peptide injection (Figure 6C).

We also induced experimental acute hepatitis in mice using Con A, which is an activated T-cell–mediated liver disease model. We then analyzed the effect of LSECtin on activated T-cell-mediated acute liver injury induced via Con A using LSECtin KO mice. Inflammatory liver injury was exacerbated with increased serum ALT/AST, and more serious liver histologic damage was observed in
the LSECtin KO compared with the wt mice (Figure 6D). The total number of lymphocytes in the liver was significantly higher in LSECtin KO mice than in wt mice (Figure 6E). Moreover, the hepatic T cells of LSECtin KO mice were found to show higher levels of TNF-α and IFN-γ compared with wt mice (Figure 6F). We also investigated the in vivo silencing effect of siRNA duplexes targeting the LSECtin gene by delivering synthetic siRNA duplexes into the mouse liver by hydrodynamic tail vein injection. In concordance with data from the LSECtin KO mice, the siRNA knock-down mice showed higher levels of plasma ALT and AST, serious liver histologic damage, and higher activity of hepatic T cells compared with wt mice (Supplementary Figure 3). Combining the results from in vitro and in vivo studies, it is reasonable to conclude that LSECtin is involved in constraining T-cell immunity in the liver.

Administration of LSECtin Protein or cDNA Plasmids In Vivo Ameliorates Acute Liver Inflammatory Injury

To show the therapeutic effect of LSECtin on Con A-induced hepatitis, 2 approaches were used. We first tried a protein therapeutic approach in which we directly administered recombinant soluble LSECtin before Con A via the tail. It was found that LSECtin protein significantly reduced disease severity, as illustrated by H&E and terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling staining, and remarkably decreased serum ALT/AST levels (Figure 7A and B). However, when given after Con A, LSECtin could not reverse established inflammation (Supplementary Figure 4). To confirm whether the protective effect was caused by suppression of T-cell activity, we determined the infiltrating lymphocyte

![Image](image-url)
subpopulations in the liver. A significant decrease in T-cell infiltration was detected in the livers of LSECtin-Fc-treated mice (Figure 7C). Moreover, LSECtin–Fc treatment decreased the numbers of TNF-α- and IFN-γ-producing T cells in liver (Figure 7D).

A soluble LSECtin cDNA plasmid was transfected into mice by hydrodynamic tail vein injection. To rule out the possibility that the soluble LSECtin protein blocks the interaction between LSECs and activated T cells, a full-length LSECtin cDNA encoding the membrane-bound protein also was transfected into mice by hydrodynamic tail vein injection. The expression of each in plasma and liver was confirmed by enzyme-linked immunosorbent assay and Q-PCR, respectively (Supplementary Figure 5). Considerable protective effects were observed in the transfected mice, which showed both a tremendous decrease in plasma ALT and AST levels (Figure 7E) and a clear amelioration of the histologic damage of hepatitis (Figure 7F). Thus, it could be concluded that LSECtin is not only a significant negative checkpoint in modulating hepatic T-cell activation, but also a new promising therapeutic target for acute liver inflammatory injury.

Discussion

The liver is a unique immunologic organ, functioning either as a site amenable to effective immune responses to pathogenic microorganisms or in the generation of tolerance to portally derived food and probiotic antigens. The dual functions of the liver require a delicate balance between immunity and tolerance.3,21 The mechanisms behind the unique immune tolerance of liver have been elucidated in the past few years. One of the principal findings is that the T-cell biology in the liver is unlike that in any other organ, highlighted by the remarkable preference for the inactivation, tolerance, and apoptosis of hepatic T cells.4 In TCR transgenic mice, activated CD8+ T cells dispersed from the lymph nodes and spleen, and an increased number of activated CD8+ T cells simultaneously were found undergoing apoptosis in the liver.22 This phenomenon appears to be specific and is evident in a variety of in vivo model systems, suggesting that the liver is a “graveyard” or “killing field” for activated T cells.2 In a mouse liver transplant model, CD4+ and CD8+ T cells were found to infiltrate significantly and then undergo apoptosis in liver allografts.23 Moreover, many clinical investigations have shown that intrahepatic hepatitis C virus–specific CD8+ T cells have functional alterations, including weak IFN-γ production, impaired proliferation, and enhanced apoptosis, which is associated with viral persistence and the progression of the disease to a chronic phase.24,25 Obviously, the unique T-cell immune response contributes greatly to specific hepatic tolerance. The exact molecular mechanisms underlying hepatic immune regulation, however, have not been elucidated clearly.

The investigation of B7-H1 and its contribution to hepatic T-cell immune regulation is noteworthy. Iwai et al5 found that expression of B7-H1 in liver sinusoidal endothelial cells and Kupffer cells could inhibit the function of activated T cells via a PD-1–dependent mechanism. Dong et al26 discovered an important role for B7-H1 in controlling the deletion of activated intrahepatic CD8+ T cells in the liver via a PD-1–independent mechanism.26 It is highly likely that hepatic immune regulation is multifactorial. Furthermore, the broad expression of B7-H1 in vivo makes it difficult to solely explain the unique characteristics of hepatic immunity. It is reasonable to speculate about other novel and specific molecular mechanisms identified in the control of hepatic immunity.

LSECtin is expressed specifically in LSECs and Kupffer cells. Its specific localization and roles in the negative regulation of T cells give rise to its important function in hepatic immunity and tolerance induction. Indeed, we showed that LSECtin negatively regulates T-cell receptor-mediated signaling and T-cell immune response stimulated by plate-bound anti-CD3 mAb; this suppression could not be overcome by co-stimulation. Moreover, the role of LSECtin in the antigen-specific activation of T cells was analyzed using T cells from TCR transgenic mice and murine LSECs with physiologic levels of LSECtin expression. The lack of LSECtin in mice resulted in increased accumulation of T cells in the liver both in normal mice and in DO11.10 TCR transgenic T-cell transfer mice. In mice with T-cell-mediated acute liver injury, KO of LSECtin accelerated the disease caused by an increased T-cell immune response, whereas exogenous administration of recombinant LSECtin protein or plasmid ameliorated the disease via down-regulation of T-cell immunity. Thus, our study provides important insight into the molecular mechanism of hepatic T-cell constraint based on investigation of the liver-specific C-type lectin LSECtin.

Recently, the importance of C-type lectin receptors (CLRs) was highlighted by the fact that they have a crucial immune regulatory role. First, CLRs on the surface of DCs could sense the extracellular environment and modulate cellular responses, especially the TLR-dependent inflammatory response.27 Second, CLRs reversibly could modulate T-cell receptor signaling and exert effects on those immune cells.10 This strongly implies that CLRs are important players in immune activation, tolerance, and homeostasis, and are involved in diseases of the immune system. It is noteworthy that several lectins also are localized to the liver, including galectin-1,7 DC-SIGN, and L-SIGN.28 None of the lectins, however, has been confirmed to be a T-cell regulator in liver thus far. In the present study, we showed that the liver-specific C-type lectin LSECtin recognized activated T cells and negatively regulated T-cell immune response in the liver. Our study not only expands the knowledge about
C-type lectins in T-cell immune regulation, but also reveals a mechanism by which the T-cell homeostasis and tolerance of the liver is regulated by C-type lectin.

Studies of the mechanisms involved in liver diseases have provided unequivocal evidence that the pathogenesis of virtually all inflammatory liver diseases involves the innate and/or adaptive immune responses. Undoubtedly, research on the mechanisms of hepatic immune regulation will provide new perspectives on liver physiology, and this knowledge will be translated rapidly into more effective therapies in the near future, similar to the noticeable progress with the T-cell regulator B7-H1 in liver diseases and other inflammatory diseases. In our study, we uncovered a novel and crucial molecular mechanism for hepatic T-cell constraint, and successfully used LSECtin protein and cDNA to treat acute liver injury. This hepatic immune regulation mechanism may provide important insights into hepatic physiology and pathophysiology and could be promising for the treatment of hepatic diseases.

Supplementary Data

Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at doi: 10.1053/j.gastro.2009.07.051.

References

Received November 12, 2008. Accepted July 9, 2009.

Reprint requests
Address requests for reprints to: Fuchu He, PhD, State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Beijing 102206, China. e-mail: hefc@nic.bmi.ac.cn; fax: (86) 10-68177417.
Acknowledgments

Li Tang and Juntao Yang were responsible for the acquisition of data, analysis and interpretation of data, and drafting of the manuscript; Wanli Liu, Xiaoming Tang, Jie Chen, Dianyuan Zhao, Min Wang, Feng Xu, Yantao Lu, Biao Liu, Qihong Sun, and Lingqiang Zhang provided technical and material support; and Fuchu He was responsible for study concept and design, study supervision, and revision of the manuscript.

L.T. and J.Y. contributed equally to this work.

Cell lines used were HL-60 (ATCC number: CCL-240), U937 (ATCC number: CRL-1593.2), Daudi (ATCC number: CCL-213), Molt-4 (ATCC number: CRL-1582), CEM (ATCC number: CCL-119), Jurkat (ATCC number: TIB-152), MCF7 (ATCC number: HTB-22TM), CHO: (ATCC number: CCL-61), and hLSEC (Sciencell 5000, Carlsbad, CA).

Complementary DNA clones used were LSECtin (GenBank accession NM_198492) and mLSECtin (GenBank accession NM_029465).

Antibodies used were from BD Pharmingen: the monoclonal antibody against CD3 (h: HIT3a; m: 500A2), anti-CD4 (RPA-T4), anti-CD8 (RPA-T8), anti-CD69 (FN50), and anti-CD25 (M-A251); Calbiochem: the monoclonal antibody against CD28 (ANC28.1/5D10); MACS: anti-mouse interleukin-2 (JES6-5H4), tumor necrosis factor-α (MP6-XT22), and interferon-γ (AN18.17.24); eBioscience: anti-mouse CD3 (145-2C11), anti-mouse CD4 (L3T4), anti-mouse CD8 (Ly-2), anti-mouse CD44 (IM7), anti-D011.10 T-cell receptor (KJ1-26), and CD28 (37.51); and BioLegend: anti-mouse CD62L (MEL-14).

Unique animals used were D011.10 mice (stock number: 003303; The Jackson Laboratory).

Conflicts of interest

The authors disclose no conflicts.

Funding

This study was supported by Chinese National Natural Science Foundation Projects (30400398, 30730050, 30621063, and 30772030), the Chinese State Key Program in Basic Research (2009CB52250, 2006CB910802, and 2006CB910800), and the Chinese National High-tech Program (2006AA02Z165).
Supplementary Figure 1. LSECtin specifically expresses in LSECs and Kupffer cells. (A) Tissue array of LSECtin expression in 42 normal human tissues. All immunohistochemically stained sections were scanned using an automated slide-scanning system at 20× magnification. (B) Highlight of LSECtin expression in liver or lymph node from tissue array. (C) Immunofluorescein staining of normal liver sections was processed using antibody against LSECtin. (D) Expression of LSECtin in LSECs. Purified LSECs were stained with anti-LSECtin mAb. (E) Expression of LSECtin in Kupffers. Normal liver sections were stained with the antibodies against LSECtin (green) and CD68 (red).
Supplementary Figure 1. (Cont’d.)
Supplementary Figure 2. LSECtin expression in liver tissue from patients with various liver diseases. (A) Tissue array of LSECtin expression in various liver diseases. All immunohistochemically stained sections were scanned using an automated slide-scanning system at 200× magnification. (B) LSECtin expression in various liver diseases evaluated by mean optical density (hemangioma, n = 10; nodular cirrhosis, n = 30; fatty degeneration, n = 15; chronic active hepatitis, n = 22; hepatocellular carcinoma, n = 25; normal hepatic tissue, n = 14).
Supplementary Figure 3. Knockdown of LSECtin accelerates acute inflammatory liver injury in mice. (A) LSECtin was down-regulated in the liver by synthetic siRNA duplexes injection. Expression of LSECtin was estimated by Q-PCR analysis. (B) The expression of LSECtin in liver at 24h, 48h and 96h after siRNA injection. Expression of LSECtin was estimated by Q-PCR analysis. (C, D) Acceleration of acute liver inflammatory injury by the knockdown of LSECtin in siRNA delivered mice. Mice were injected with control siRNA or LSECtin siRNA and then administered with Con A. After 24h, plasma ALT/AST levels were measured (C), and liver samples were collected for hematoxylin-eosin staining (D).

Supplementary Figure 4. LSECtin did not reverse established inflammation induced by Con A. (A) Mice were treated with control-Fc or LSECtin-Fc 3 hours after Con A injection. After 24 hours, plasma ALT/AST levels were measured. (B) After 6-hour treatment with Con A, the T cells in mouse liver were separated and stimulated with immobilized anti-CD3 antibody plus LSECtin-Fc. Cytokine expression in the supernatants was determined by ELISA.
Supplementary Figure 5. The expression of soluble and full-length LSECtin cDNA plasmid mice were injected with soluble or full-length LSECtin cDNA plasmids. Plasma LSECtin protein was measured by ELISA-based assay at 6, 12, 24, 36, and 48 h (A). LSECtin mRNA in liver was estimated by Q-PCR analysis at 12 h (B).